At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Semaglutide +1 morebiological
Likely dose
Semaglutide 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study
In Brief
A Phase 2 clinical trial evaluating Semaglutide and Placebo for Major Depressive Disorder. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2021
Primary CompletionDec 2024
TodayJul 2026
First PostedJul 10, 2020
Enrollment StartOct 6, 2021
Primary CompletionDec 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.0 years ago
Interventions
Semaglutidebiological
3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
Placebobiological
Semaglutide placebo capsules